A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient

Therapeutic Apheresis and Dialysis

Volumn 11, Issue 3, 2007, Pages 235-240

  Abe, Masanori ^a   Kaizu, Kazo ^b   Matsumoto, Koichi ^a  

^a NIHON UNIVERSITY   (Japan)

^b Yokohama Social Insurance Central Hospital   (Japan)

Author keywords

Acute renal failure; Continuous hemodiafiltration; Edaravone; Fulminant hepatitis; Plasma exchange

Indexed keywords

AMLODIPINE BESYLATE; CANDESARTAN HEXETIL; DOPAMINE; NAFAMSTAT MESILATE; NORPHENAZONE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BRAIN INFARCTION; CASE REPORT; DISSEMINATED INTRAVASCULAR CLOTTING; DYSARTHRIA; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEMIPLEGIA; HEMODIAFILTRATION; HEMODIALYSIS; HEPATITIS; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERTENSION; LABORATORY TEST; LIVER BIOPSY; LYMPHOCYTE TRANSFORMATION TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; SHOCK; TREATMENT OUTCOME; URINE VOLUME;

ANTIPYRINE; CEREBRAL INFARCTION; DISSEMINATED INTRAVASCULAR COAGULATION; FREE RADICAL SCAVENGERS; HEPATITIS; HUMANS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; PLASMA EXCHANGE; RENAL DIALYSIS;

EID: 34248173436     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00480.x     Document Type: Article

References (24)

1. The Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003 15 : 222 9.
2. Houkin K, Nakayama N, Kamada K, Noujou T, Abe H, Kashiwaba T. Neuroprotective effect of the free radical scavenger MCI-186 in patients with cerebral infarction. Clinical evaluation using magnetic resonance imaging and spectroscopy. J Stroke Cerebrovasc Dis 1998 5 : 315 22.
3. Mishina M, Komaba Y, Kobayashi S et al. Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction. Neurol Med Chir 2005 45 : 344 8.
4. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988 19 : 480 5.
5. Bromont C, Marie C, Bralet J. Increased lipid peroxidation in vulnerable brain regions after transient forebrain ischemia in rats. Stroke 1989 20 : 918 24.
6. Chan PH, Fishman RA, Longer S, Chen S, Yu A. Cellular and molecular effects of polyunsaturated fatty acids in brain ischemia and injury. Prog Brain Res 1985 63 : 227 35.
7. Watanabe T, Morita I, Nishi H, Murota S. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988 33 : 81 7.
8. Mizuno A, Umemura K, Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol 1998 30 : 575 8.
9. Ando K, Nishi H, Watanabe T et al. General pharmacological studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), a novel radical scavenging agent. Jpn Pharmacol Ther 1997 25 : 1723 53.
10. Tsuji K, Kwon A-H, Yoshida H et al. Free radical scavenger (edaravone) prevents endotoxin-induced liver injury after partial hepatectomy in rats. J Hepatol 2005 42 : 94 101.
11. Sueishi K, Mishima K, Makino K et al. Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats. Eur J Pharmacol 2002 451 : 203 8.
12. Satoh M, Kashihara N, Fujimoto S et al. A novel free radical scavenger, edaravone, protects against cisplatin-induced acute renal damage in vitro and in vivo. J Pharmacol Exp Ther 2003 305 : 1183 90.
13. Doi K, Suzuki Y, Nakao A, Fujita T, Noiri E. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. Kidney Int 2004 65 : 1714 23.
14. Hirasawa H, Oda S, Shiga H, Matsuda K. Endotoxin adsorption or hemodiafiltration in the treatment of multiple organ failure. Curr Opin Crit Care 2000 6 : 421 5.
15. Matsuda K, Hirasawa H, Oda S, Shiga H, Nakanishi K. Current topics on cytokine removal technologies. Ther Apher 2001 5 : 306 14.
16. Nakae H, Yonekawa C, Moon S, Tajima K. The series-parallel circuit in the treatment of fulminant hepatitis. Ther Apher Dial 2004 8 : 153 9.
17. Kita Y, Uchita K, Kajimoto Y, Taniguchi M, Kusumi H, Abe T. Study of plasma-exchange combined with bicarbonate dialysis using various substitution fluids. Ther Plasmapheresis 1982 II : 155 8.
18. Kaplan AA, Epstein M. Extracorporeal blood purification in the management of patients with hepatic failure. Semin Nephrol 1997 17 : 576 82.
19. Yorgin PD, Eklund DK, al-Uzri A, Whitesell L. Concurrent centrifugation plasmapheresis and continuous venovenous hemodiafiltration. Pediatr Nephrol 2000 14 : 18 21.
20. Yoshiba M, Inoue K, Sekiyama K, Koh I. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. Artif Organs 1996 20 : 1169 72.
21. Sadahiro T, Hirasawa H, Oda S et al. Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure. Crit Care Med 2001 28 : 1386 92.
22. Nakae H, Yonekawa C, Wada H, Asanuma Y, Sato T, Tanaka H. Effectiveness of combining plasma exchange and continuous hemodiafiltration (combined modality therapy in a parallel circuit) in the treatment of patients with acute hepatic failure. Ther Apher 2001 5 : 471 5.
23. Nakae H, Asanuma Y, Tajimi K. Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients. Ther Apher 2002 6 : 419 24.
24. Abe T, Kobata H, Hanba Y et al. Study of plasma exchange for liver failure: beneficial and harmful effects. Ther Apher Dial 2004 8 : 180 4.